Beigene Ltd., of Beijing, presented updated phase I data at the International Conference on Malignant Lymphoma meeting in Lugano, Switzerland, showing that BTK inhibitor BGB-3111 continues to be well-tolerated in patients with Waldenström’s macroglobulinemia (WM), with a very good partial response rate of 43 percent and with an overall response rate of 90 percent (38 of 42 efficacy-evaluable patients), with a median follow-up time of 12.3 months.